| |
Tuesday, October 11, 2022 | 10am ET / 7am PT Join us to learn about common pitfalls for rAAV processing and ways to overcome the challenges. Key for a successful process are high viral genome productivity and full capsids in the harvest material, with high overall yield and efficient impurity removal. Register now.
|
|
Today's Big NewsOct 6, 2022 |
| By Nick Paul Taylor Eli Lilly has joined Schrödinger’s growing stable of drug development partners, putting up $425 million in milestones to access small-molecule candidates against an undisclosed target. |
|
|
|
By Max Bayer Cyclerion is shifting its clinical gears once more, divesting from targets in the central nervous system to focus instead on mitochondria-focused diseases. The pivot is resulting in layoffs for 45% of the workforce. |
By Nick Paul Taylor TauRx Pharmaceuticals is set to test the regulatory bar for approval of Alzheimer’s disease drugs in the post-Aduhelm world. The company was unable to show how its drug candidate performed compared to the control arm in a phase 3 clinical trial—but it plans to use the dataset to seek approval anyway. |
By Gabrielle Masson Boehringer Ingelheim has its eyes on Surrozen, paying the California biotech $12.5 million cash for its preclinical asset designed to help regenerate healthy eye and potentially reverse retinal disease. |
By James Waldron Nested Therapeutics has emerged from stealth mode with $125 million in the bank to fund its preclinical pipeline of precision medicines for hard-to-treat cancers. The money includes $90 million from a concurrent series A led by Goldman Sachs’ life sciences investment arm. |
By Max Bayer Amgen is the second Big Pharma in roughly two weeks to unveil a new R&D facility in San Francisco, opening a 245,000-square-foot site in Oyster Point. The company says the facility will host up to 650 staff. |
By Joseph Keenan Sanofi has inked a partnership with clinical study tech company TrialSpark in an effort to leverage novel methods to help identify and bring new drugs to market. |
By Helen Floersh Scientists have characterized the mechanism by which reactive oxygen species protect intestinal cells from excessive inflammation, opening the door to new IBD treatments. |
By Joseph Keenan Bristol Meyers Squibb has high expectations for ConcertAI's digital solution for clinical trials, suggesting it could become the "gold standard" for studying oncology therapies. |
By Conor Hale That amounts to five hits from the collaboration so far, with the latest additions aimed at chronic kidney disease and idiopathic pulmonary fibrosis. |
By Fraiser Kansteiner Wednesday, the U.S. Department of Health and Human Services (HHS) said it’s throwing down $290 million to lock up an undisclosed amount of Amgen’s blood disorder med Nplate, which is approved to treat blood cell injuries linked to acute radiation syndrome (ARS) in kids and adults. |
By Kevin Dunleavy Four former Bristol Myers Squibb employees who were fired by the company for refusing to be vaccinated against COVID-19 have filed a lawsuit. They claim BMS did not properly consider making accommodations for their religious beliefs. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about how how frequent cyberattacks are impacting patient care and what hospitals and health systems can do to shore up their defenses. Also under discussion is how social drivers of health are finally being recognized by the CMS. |
|
|---|
|
|
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
